Davies Mary-Ann, Morden Erna, Rosseau Petro, Arendse Juanita, Bam Jamy-Lee, Boloko Linda, Cloete Keith, Cohen Cheryl, Chetty Nicole, Dane Pierre, Heekes Alexa, Hsiao Nei-Yuan, Hunter Mehreen, Hussey Hannah, Jacobs Theuns, Jassat Waasila, Kariem Saadiq, Kassanjee Reshma, Laenen Inneke, Le Roux Sue, Lessells Richard, Mahomed Hassan, Maughan Deborah, Meintjes Graeme, Mendelson Marc, Mnguni Ayanda, Moodley Melvin, Murie Katy, Naude Jonathan, Ntusi Ntobeko A B, Paleker Masudah, Parker Arifa, Pienaar David, Preiser Wolfgang, Prozesky Hans, Raubenheimer Peter, Rossouw Liezel, Schrueder Neshaad, Smith Barry, Smith Mariette, Solomon Wesley, Symons Greg, Taljaard Jantjie, Wasserman Sean, Wilkinson Robert J, Wolmarans Milani, Wolter Nicole, Boulle Andrew
Health Intelligence, Western Cape Government: Health and Wellness, South Africa.
Centre for Infectious Disease Epidemiology and Research, School of Public Health and Family Medicine, University of Cape Town, South Africa.
medRxiv. 2022 Jul 1:2022.06.28.22276983. doi: 10.1101/2022.06.28.22276983.
We aimed to compare clinical severity of Omicron BA.4/BA.5 infection with BA.1 and earlier variant infections among laboratory-confirmed SARS-CoV-2 cases in the Western Cape, South Africa, using timing of infection to infer the lineage/variant causing infection.
We included public sector patients aged ≥20 years with laboratory-confirmed COVID-19 between 1-21 May 2022 (BA.4/BA.5 wave) and equivalent prior wave periods. We compared the risk between waves of (i) death and (ii) severe hospitalization/death (all within 21 days of diagnosis) using Cox regression adjusted for demographics, comorbidities, admission pressure, vaccination and prior infection.
Among 3,793 patients from the BA.4/BA.5 wave and 190,836 patients from previous waves the risk of severe hospitalization/death was similar in the BA.4/BA.5 and BA.1 waves (adjusted hazard ratio [aHR] 1.12; 95% confidence interval [CI] 0.93; 1.34). Both Omicron waves had lower risk of severe outcomes than previous waves. Prior infection (aHR 0.29, 95% CI 0.24; 0.36) and vaccination (aHR 0.17; 95% CI 0.07; 0.40 for boosted vs. no vaccine) were protective.
Disease severity was similar amongst diagnosed COVID-19 cases in the BA.4/BA.5 and BA.1 periods in the context of growing immunity against SARS-CoV-2 due to prior infection and vaccination, both of which were strongly protective.
我们旨在比较南非西开普省实验室确诊的新冠病毒病例中,奥密克戎BA.4/BA.5感染与BA.1及更早变异株感染的临床严重程度,利用感染时间来推断引起感染的谱系/变异株。
我们纳入了2022年5月1日至21日(BA.4/BA.5波)及之前同等时间段内年龄≥20岁、实验室确诊为新冠肺炎的公共部门患者。我们使用经人口统计学、合并症、入院时血压、疫苗接种和既往感染调整的Cox回归,比较各波次之间(i)死亡风险和(ii)严重住院/死亡风险(均在诊断后21天内)。
在BA.4/BA.5波的3793例患者和之前波次的190836例患者中,BA.4/BA.5波和BA.1波的严重住院/死亡风险相似(调整后风险比[aHR]为1.12;95%置信区间[CI]为0.93;1.34)。奥密克戎的两个波次严重结局的风险均低于之前的波次。既往感染(aHR为0.29,95%CI为0.24;0.36)和疫苗接种(加强接种与未接种疫苗相比,aHR为0.17;95%CI为0.07;0.40)具有保护作用。
在因既往感染和疫苗接种而对新冠病毒免疫力增强的背景下,BA.4/BA.5和BA.1时期确诊的新冠肺炎病例的疾病严重程度相似,既往感染和疫苗接种均具有很强的保护作用。